Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible. He adds that they've identified multiple revenue generating partnering opportunities for its NanoCelle® drug delivery platform which he says can improve the efficacy of multiple medicines and therapeutics.
Medlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle partnering opportunities
